Flagyl 400mg Tablets

  • Name:

    Flagyl 400mg Tablets

  • Company:
    info
  • Active Ingredients:

    Metronidazole

  • Legal Category:

    Product subject to restricted prescription (C)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/07/18

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/7/2018

Click on this link to Download PDF directly

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 176 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 July 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 20 July 2018 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

 

 

4.4 Special warnings and special precautions for use

 

Wording replaced in paragraph with:-

 

  • (SJS),
  • (TEN) or acute generalised exanthematous pustulosis (AGEP)
  • AGEP
  • must be immediately

 

4.8 Undesirable effects

 

Skin and subcutaneous tissue disorders

 

Wording added into paragragh

 

  • acute generalised exanthematous pustulosis

Updated on 22 December 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to restricted prescription (C)

Updated on 22 December 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Update section 4.4

Updated on 20 December 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 20 December 2016 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 19 August 2016 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

 

4.8             Undesirable effects

Frequency, type and severity of adverse reactions in children are the same as in adults.

 

 

            Gastrointestinal disorders

-     epigastric pain, nausea, vomiting, malaise, diarrhoea.

-     oral mucositis, taste disorders, dry mouth, anorexia.

-     reversible cases of pancreatitis.

-     tongue discolouration/furry tongue.

 

Immune system disorders

-           angioedema,  anaphylactic shock.

           

           Nervous system disorders

-     peripheral sensory neuropathy, paraesthesia

-          headache, convulsions, dizziness.

-          reports of encephalopathy (e.g. confusion) and subacute cerebellar syndrome (e.g. ataxia, dysathria, gait impairment, nystagmus and tremor) which may resolve with discontinuation of the drug.

-          aseptic meningitis

 

Psychiatric disorders

-          psychotic disorders including confusion, hallucinations

-          depressed mood

 

Eye disorders

-     transient vision disorders such as diplopia, myopia, blurred vision, decreased visual acuity, changes in color vision.

-     Optic neuropathy/neuritis.

 

Ear and labyrinth disorders

-          hearing impaired/hearing loss (including sensorineural)

-          tinnitus

 

Blood and lymphatic system disorders

-     cases of agranulocytosis, neutropenia and thrombocytopenia have been reported.

 

Hepatobiliary disorders

-      increase in liver enzymes (AST, ALT, alkaline phosphatase), cholestatic or mixed hepatitis and hepatocellular liver injury, sometimes with jaundice, have been reported.

-      cases of liver failure requiring liver transplant have been reported in patients treated with metronidazole mostly when used in combination with other antibiotic drugs.

 

Skin and subcutaneous tissue disorders

-      rash, pruritus, flushing, urticaria

-      pustalar eruptions

-      fixed drug eruption

-      Stevens-Johnson syndrome, toxic epidermal necrolysis.

 

General disorders and administration site conditions

-  fever

 

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRAPharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;  Fax: +353 1 6762517. Website: www.hpra.ie; e-mail: medsafety@hpra.ie

Updated on 18 August 2016 PIL

Reasons for updating

  • Change to side-effects

Updated on 4 April 2014 PIL

Reasons for updating

  • Change to side-effects

Updated on 19 March 2014 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Type II.C.1.4 variation to update the SPC for the product range following the revision of the Core Safety Data Sheet for metronidazole. The update concerns the addition of adverse events to section 4.8 of the SPC.

Updated on 26 April 2013 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section 6.3: Shelf life reduced
Section 6.4: Changed to Store below 30º C in the original packaging (protect from light).
Section 7: Addition of 'Sanofi' as a trading style

Updated on 25 April 2013 PIL

Reasons for updating

  • Change to storage instructions
  • Change to date of revision
  • Change to marketing authorisation holder

Updated on 5 March 2013 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

Section 4.8 updated re Hepatic disorders

Updated on 27 November 2012 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to restricted prescription (C)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 21 December 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 23 September 2009 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 6 May 2008 PIL

Reasons for updating

  • New PIL for medicines.ie